Systemic inflammatory response and survival in patients with localised prostate cancer: 10-year follow-up

Urologia Internationalis

Volumn 84, Issue 4, 2010, Pages 430-434

  McArdle, Peter A ^a   Qayyum, Tahir ^a   McMillan, Donald C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

C reactive protein; Gleason score; Prostate cancer; Prostate specific antigen

Indexed keywords

C REACTIVE PROTEIN; AUTACOID; PROSTATE SPECIFIC ANTIGEN;

AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; AGE; BLOOD; CROSS-SECTIONAL STUDY; EPIDEMIOLOGY; IMMUNOLOGY; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SURVIVAL; SURVIVOR; TIME; TREATMENT OUTCOME; TUMOR INVASION; UNITED KINGDOM;

AGE FACTORS; AGED; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; HUMANS; INFLAMMATION MEDIATORS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SCOTLAND; SURVIVAL ANALYSIS; SURVIVORS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953215458     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313364     Document Type: Article

References (24)

1. Cancer statistics, Cancer Research UK. www.cancerresearchuk.org.
2. SEER Program and Monograph Data: National Cancer Institute. www.seer.cancer. gov.
3. Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Adami HO, Johansson JE, Scandinavian Prostate Cancer Group Study Number 4: Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008; 100: 1144-1154.
4. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001; 537: 539-545.
5. Coussens LM, Werb Z: Inflammation and cancer. Nature 2002; 420: 860-867.
6. Vakkila J, Lotze MT: Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004; 4: 641-648.
7. McMillan DC, Canna K, McArdle CS: A systemic inflammatory response predicts survival following curative resection for colorectal cancer. Br J Surg 2003; 90: 215-219. (Pubitemid 36237897)
8. Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R, Imrie CW: Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. Br J Cancer 2005; 92: 21-23.
9. Crumley ABC, McMillan DC, McKernan M, Going JR, Stuart RC: The relationship between the pre-operative systemic inflammatory response and cancer specific survival in patients undergoing potentially curative resection for gastro-oesophageal cancer. Br J Cancer 2006; 94: 1568-1571.
10. Lamb GWA, McMillan DC, Ramsey S, Aitchison M: Pre-operative systemic inflammatory response predicts cancer specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br J Cancer 2006; 94: 781-784.
11. Iimura Y, Saito K, Fujii Y, Kumagai J, Kawakami S, Komai Y, Yonese J, Fukui I, Kihara K: Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol 2009; 181: 1004-1012.
12. Hilmy M, Bartlett JM, Underwood MA, Mc- Millan DC: The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer 2005; 92: 625-627.
13. Yoshida S, Saito K, Koga F, Yokoyama M, Kageyama Y, Masuda H, Kobayashi T, Kawakami S, Kihara K: C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int 2008; 101: 978-981.
14. McArdle PA, Mir K, Almushatat AS, Wallace AM, Underwood MA, McMillan DC: Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int 2006; 77: 127-129.
15. Nakashima J, Kikuchi E, Miyajima A, Nakagawa K, Oya M, Ohigashi T, Murai M: Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases. Urol Int 2008; 80: 129-133.
16. Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, Henner WD, Ryan CW, Venner P, Ruether JD, Chi KN, ASCENT Investigators: C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer 2008; 112: 2377-2383.
17. European Association of Urology: Guidelines on Prostate Cancer. www.uroweb.org.
18. Ataman F, Zurlo A, Artignan X, van Tienhoven G, Blank LE, Warde P, Dubois JB, Jeanneret W, Keuppens F, Bernier J, Kuten A, Collette L, Pierart M, Bolla M: Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863. Eur J Cancer 2004; 40: 1674-1681.
19. Gabay C, Kushner I: Mechanisms of disease: acute phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
20. Pepys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-1812.
21. Corcoran NM, Costello AJ: Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer? BJU Int 2003; 91: 545-553.
22. Okamoto M, Lee C, Oyasu R: Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997; 57: 141-146. (Pubitemid 27020343)
23. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC: Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate 2000; 42: 239-242. (Pubitemid 30080423)
24. Chung TD, Yu JJ, Kong TA, Spiotto MT, Lin JM: Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate 2000; 42: 1-7.